bone resorption/iiveldus

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 42 tulemused

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Metastatic bone disease (MBD) is a frequent complication in patients with breast cancer and is associated with significant morbidity. This study assessed the pharmacokinetics, efficacy, and safety of odanacatib, a selective Cat K inhibitor, in reducing markers of bone resorption in women with breast

The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

This postmarketing surveillance study assessed the safety and effectiveness of daily teriparatide treatment in patients with osteoporosis in a Japanese clinical setting. In this prospective, multicenter, observational study, patients with osteoporosis at high risk for fracture received subcutaneous

Alendronate: an update of its use in osteoporosis.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Oral alendronate 5 or 10 mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal women with or without osteoporosis, in men with

Zoledronic acid.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D3-induced hypercalcaemia in a rat model and calcium release in vitro. A single 5-minute intravenous

Bisphosphonates in the treatment of disorders of mineral metabolism.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Bisphosphonates are analogues of inorganic pyrophosphate, a naturally occurring chemical in bone. In vitro and animal experiments demonstrated that these agents were effective inhibitors of bone resorption. Subsequently they were applied to a variety of clinical problems in which increased bone

Endoscopic resection of a mucocele of the crista galli.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Mucoceles expand by the process of bone resorption and new bone formation, which leads to local destruction and displacement of adjacent structures. We present the case of a 47-year-old woman who presented with recurrent headaches, nausea, and vomiting, all of which were believed to have occurred

CO-EXISTENCE OF PRIMARY HYPERPARATHYROIDISM DUE TO MULTIPLE ENDOCRINE NEOPLASIA 1 IN A HYPERCALCEMIC PATIENT WITH GRAVES DISEASE.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Hypercalcemia in a patient with Graves disease can occur in up to 22% of cases. The mechanism is thought to be increased bone resorption. There are more rare causes of hypercalcemia in these patients with hyperthyroidism, such as hyperparathyroidism, which occurs in less than 1% of

Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The effects of teriparatide when given in combination with HRT were studied in postmenopausal women with low bone mass or osteoporosis. The data provide evidence that the adverse event profile for combination therapy with teriparatide + HRT together is consistent with that expected for each

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

This phase II study evaluated single-agent bosutinib in pretreated patients with locally advanced or metastatic breast cancer.Patients received oral bosutinib 400 mg/day. The primary end point was the progression-free survival (PFS) rate at 16 weeks.

[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE To evaluate the efficacy and safety of zoledronic acid in the treatment of bone pain in patients with bone metastasis from solid tumor or multiple myeloma. METHODS A randomized, double-blind, double-simulated and multi-center phase III clinical trail with pamidronate as control was

[The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Hormone refractory prostate cancer is dominated by osseous metastases. Bisphosphonates are able to reduce bone resorption. Sixteen hormone refractory prostate cancer patients with related bone metastases were included in the study. Group A consisted of patients who were not treated with

Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Parathyroid hormone-related protein (PTHrP) plays a central role in humoral hypercalcemia of malignancy (HHM), which is one of the most frequent paraneoplastic syndromes. PTHrP produced by the tumor acts through a common PTH/PTHrP receptor to promote bone resorption, inhibit calcium excretion from

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Bone metastases typically are associated with osteolytic bone destruction, resulting in bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. Bisphosphonates are potent inhibitors of normal and pathologic bone resorption and represent a significant therapeutic

Strontium ranelate for the management of osteoporosis.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE To evaluate the role of strontium ranelate in the management of osteoporosis. METHODS A MEDLINE (January 1966 to May 2007) search using the terms osteoporosis, strontium ranelate, bonemineral density, and fractures. METHODS All English-language articles identified from the data sources

Spotlight on strontium ranelate: in postmenopausal osteoporosis.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

This is a review of the pharmacology of strontium ranelate (Protelos, Protos, Protaxos, Bivalos, Osseor), and its efficacy and tolerability in the treatment of patients with postmenopausal osteoporosis. Strontium ranelate is a divalent strontium salt of ranelic acid that is capable of increasing

Eelmine
1
2
3
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel